Cupric Sulfate
drugOn this page
Also known as Copper (as cupric sulfate)Copper (as sulfate)Copper sulfateCopper sulfate pentahydrateanhydrousCopper(ii) sulfate, anhydrousCopper(ii) tetraoxosulfateCupric sulfate anhydrousCupric sulfate component of multrysCupric sulfate component of tralementCupric sulfate pentahydrateCupric sulphateCupric sulphate anhydrousCupric sulphate pentahydrateCuprum sulphuricumCaustic powderE519NSC-57630CuSO4.5H2O
Summary
Cupric Sulfate (CHEMBL604) is an approved small molecule (ATC V03AB20); indicated across 3 conditions including iron deficiency anemia and anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V03AB20
- Indications: 3 conditions
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL604 |
| Name | Cupric Sulfate |
| Type | Small molecule |
| Max phase | 4 |
| ATC | V03AB20 |
Also known as: Copper (as cupric sulfate), Copper (as sulfate), Copper sulfate, Copper sulfate pentahydrate, anhydrous, Copper(ii) sulfate, anhydrous, Copper(ii) tetraoxosulfate, Cupric sulfate, Cupric sulfate anhydrous, Cupric sulfate component of multrys, Cupric sulfate component of tralement, Cupric sulfate pentahydrate
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| iron deficiency anemia | 4 | MONDO:0001356 | HP:0001891 |
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00846144 | Not specified | UNKNOWN | The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: iron deficiency anemia, anemia